Extramedullary Hematopoiesis in the Absence of Myeloproliferative Neoplasm: Mayo Clinic Case Series of 309 Patients
Conclusions:We present the largest experience in EMH without associated MPN, in adults. We describe associated conditions and elaborate further on "idiopathic" EMH (n=12), which often represented an incidental discovery during evaluation of unrelated symptoms. None of the patients with idiopathic EMH harbored occult malignancies or subsequently developed MPN or other myeloid malignancies. Our observations do not support undertaking extensive investigations targeting MPN or other malignancies in idiopathic EMH and simple monitoring might be adequate.DisclosuresNo relevant conflicts of interest to declare.
Publication date: Available online 17 November 2019Source: European UrologyAuthor(s): Zhengzheng Xu, Guangzhe Ge, Bao Guan, Zhentao Lei, Xueyu Hao, Yuanyuan Zhou, Yue Shi, Huan Lu, Jilu Wang, Ding Peng, XiKang Wu, Huiying He, Bao Zhang, Xuesong Li, Liqun Zhou, Weimin Ci
Publication date: Available online 16 November 2019Source: European UrologyAuthor(s): Pirus Ghadjar, Thomas Wiegel
Publication date: Available online 16 November 2019Source: European UrologyAuthor(s): Elise De Bleser, Piet Ost
ConclusionsTattooing of axillary LNs is safe and easily performed. Tattooing was helpful in identifying the marked LN in the majority of cases. This technique helps to ensure that metastatic LNs are identified and removed at surgery after NAT.
So in this "fellowship" that i resigned from recently, I asked long time ago whether tail was covered.I was told yes. When I signed paperwork after resigining I was told that I'd be covered for the premium for the tail. When I was like what?! That's not what I was told. I was told that "it would be covered if I finished the fellowship." That seems shady and illegal. Obviously paying thousands of dollars for tail would be reasonable on an attending salary, but now it seems they are pissed I... Tail coverage
Individuals who have multiple close relatives with pancreatic cancer should undergo surveillance for pancreatic cancer, according to updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium.Reuters Health Information
The objectives of our study were to (i) examine the rate of vesico-ureteral injury at benign hysterectomy by surgical approach and (ii) compare the risk of vesico-ureteral injury specifically between minimally-invasive laparoscopic and abdominal hysterectomy on a populational level.DesignRetrospective population-based observational study.SettingThe National Inpatient Sample.Patients501,110 women who underwent hysterectomy for benign gynecological disease from 1/2012-9/2015 were included: total abdominal hysterectomy (TAH, n=284,365 [56.7%]), total laparoscopic hysterectomy (TLH, n=60,410, [12.1%]), abdominal supracerv...
Publication date: Available online 16 November 2019Source: Gynecologic Oncology ReportsAuthor(s): Hermineh Aramin, Pratistha Koirala, Abhishek Shah, Kendall Adams, Natalia Buza, Sapna Desai, Melissa Fairbairn, David Goldenberg, Wenli Gao, Linus Chuang, Ramapriya Vidhun, Vaagn Andikyan
Publication date: Available online 16 November 2019Source: American Journal of Infection ControlAuthor(s): Patrick Murphy, Le Kang, Michele Fleming, Connie Atkinson, Rachel Pryor, Kaila Cooper, Emily Godbout, Michael P. Stevens, Michelle Doll, Gonzalo BearmanWe employed an interrupted time series analysis to assess the impact of ultraviolet-C light disinfection at terminal discharge in an oncology unit and a bone marrow transplant unit on the incidence of hospital-acquired infections. The deployment of ultraviolet-C light disinfection was associated with a significant decrease in the rate of Clostridioides difficile infect...
Publication date: Available online 17 November 2019Source: Pharmacological ResearchAuthor(s): Ali Dehshahri, Milad Ashrafizadeh, Elham Ghasemipour Afshar, Abbas Pardakhty, Ali Mandegary, Reza Mohammadinejad, Gautam SethiAbstractTopoisomerase enzymes have shown unique roles in replication and transcription. These enzymes which were initially found in Escherichia coli have attracted considerable attention as target molecules for cancer therapy. Nowadays, there are several topoisomerase inhibitors in the market to treat or at least control the progression of cancer. However, significant toxicity, low solubility and poor pharm...
More News: Acute Leukemia | Acute Myeloid Leukemia | Anemia | Back Pain | Bone Marrow Aspiration and Biopsy | Cancer | Cancer & Oncology | Chronic Leukemia | Chronic Lymphocytic Leukemia | Chronic Pain | Databases & Libraries | Genetics | Hematology | Leukemia | Liver | Liver Transplant | Lung Transplant | Lymphoma | Myelodysplastic Syndrome | Myeloproliferative Disorders | Non-Hodgkin's Lymphoma | Pain | Pain Management | Pathology | Splenectomy | Study | Transplant Surgery | Transplants | Ureter and Renal Pelvis Cancer | Urology & Nephrology